180 Life Sciences Corp. (NASDAQ:ATNF) Short Interest Down 50.4% in February

180 Life Sciences Corp. (NASDAQ:ATNF) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 25,900 shares, a decline of 50.4% from the January 31st total of 52,200 shares. Approximately 1.5% of the company’s stock are short sold. Based on an average daily volume of 409,700 shares, the short-interest ratio is currently 0.1 days.

180 Life Sciences Price Performance

NASDAQ:ATNF opened at $1.17 on Friday. The business’s 50 day moving average is $1.57 and its two-hundred day moving average is $2.09. 180 Life Sciences has a 52 week low of $1.10 and a 52 week high of $17.75.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Wednesday, February 19th.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC purchased a new position in 180 Life Sciences Corp. (NASDAQ:ATNF) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned about 2.20% of 180 Life Sciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.